Spectroscopy and near-infrared to visible upconversion of er3+ ions in aluminosilicate glasses manufactured with controlled optical transmission

In this work we report on the spectroscopic properties and the near-infrared to visible upconversion of Er3+ ions in aluminosilicate glasses manufactured by directionally solidification with the laser floating zone technique. Glasses were manufactured in a controlled oxidizing atmosphere to provide them with high optical transmission in the visible spectral range. Absorption and emission spectra, and lifetimes were assessed in both the visible and the near infrared spectral range. Green upconversion emissions of the2H11/2¿4I15/2 and4S3/2¿4I15/2 transitions at 525 nm and 550 nm attributed to a two-photon process were observed under excitation at 800 nm. Mechanisms responsible for the upconversion luminescence were discussed in terms of excited state absorption and energy transfer upconversion processes. Excitation spectra of the upconverted emission suggest that energy transfer upconversion processes are responsible for the green upconversion luminescence

On the control of optical transmission of aluminosilicate glasses manufactured by the laser floating zone process

In this work, a detailed study of the properties of aluminosilicate glass rods manufactured by means of the laser floating zone (LFZ) technique is presented. Samples fabrication was carried out in controlled atmosphere using air, nitrogen, and oxygen. Transmission spectra showed that glasses manufactured in oxygen presented high optical transmission in the visible spectral range compared to those manufactured in other environments, thus allowing us to tune their optical behavior between transparent and nearly opaque through the control of the surrounding atmosphere. Microstructure and thermo- mechanical properties were also assessed, showing similar hardness, toughness, flexural strength and glass transition temperature values, and in the same range as other aluminosilicate glasses. Compositional and structural characterization in terms of energy dispersive X-ray spectroscopy (EDX) and electron paramagnetic resonance (EPR) allowed us to determine the origin of optical transmission dependence on the fabrication atmosphere

Microstructural and magnetic characterization of Fe- and Ir-based multilayers

Nominal [Fe(t)/Ir(t'')](n) (M/Mtype), [FeOx(t)/IrOx(t'')](n) (O/O), and [Fe(t)/IrOx(t'')](n) (M/O) multilayers have been prepared by magnetron sputtering at room temperature. Composition, structure, and magnetic behavior have been analyzed. In the M/M samples, the Fe and Ir phases are identified as bcc and fcc, respectively. The magnetism evolves from bulklike iron to granular behavior as the thickness of the Fe layers decreases. An induced magnetic moment, ferromagnetically coupled to Fe, is observed on Ir by x-ray magnetic circular dichroism (XMCD). Besides, the presence of negative remanent magnetization is observed in the M/M samples. As for the M/O samples, the stronger affinity of iron for oxygen displaces the oxygen atoms giving rise to actual heterostructures that strongly differ from the nominal ones. For similar thickness of the two layers the Fe layer become oxidized while a mixture of metal and oxide phases is found in the Ir layer. The increase of the Fe thickness leads to a metallic Ir layer and a highly coercive (similar to 4.4 kOe) core-shell metal-oxide structure in the Fe layers

Microstructural and magnetic characterization of Fe- and Ir-based multilayers

Nominal [Fe(t)/Ir(t′)]n (M/M type), [FeOx(t)/IrOx(t′)]n (O/O), and [Fe(t)/IrOx(t′)]n (M/O) multilayers have been prepared by magnetron sputtering at room temperature. Composition, structure, and magnetic behavior have been analyzed. In the M/M samples, the Fe and Ir phases are identified as bcc and fcc, respectively. The magnetism evolves from bulklike iron to granular behavior as the thickness of the Fe layers decreases. An induced magnetic moment, ferromagnetically coupled to Fe, is observed on Ir by x-ray magnetic circular dichroism (XMCD). Besides, the presence of negative remanent magnetization is observed in the M/M samples. As for the M/O samples, the stronger affinity of iron for oxygen displaces the oxygen atoms giving rise to actual heterostructures that strongly differ from the nominal ones. For similar thickness of the two layers the Fe layer become oxidized while a mixture of metal and oxide phases is found in the Ir layer. The increase of the Fe thickness leads to a metallic Ir layer and a highly coercive (∼4.4 kOe) core-shell metal-oxide structure in the Fe layers.Spanish Ministry of Economy and Competitiveness (MINECO), MAT2014-54425-R, MAT2017-83468-RAragón DGA NETOSHIM

Dimensionality-driven metal-insulator transition in spin-orbit-coupled IrO_2

A metal-insulator transition is observed in spin-orbit-coupled IrO_2 thin films upon reduction of the film thickness. In the epitaxially grown samples, the critical thickness (t similar to 1.5-2.2 nm) is found to depend on growth orientation (001), (100) or (110). Interestingly from the applied point of view, the insulating behavior is found even in polycrystalline ultrathin films. By analyzing the experimental electrical response with various theoretical models, we find good fits to the Efros-Shklovskii-VRH and the Arrhenius-type behaviors, which suggests an important role of electron correlations in determining the electrical properties of IrO_2. Our magnetic measurements also point to a significant role of magnetic order. Altogether, our results would point to a mixed Slater- and Mott-type of insulator

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. METHODS AND RESULTS: GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%. Anticoagulant treatment was associated with a 35% lower risk of death. CONCLUSION: The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362